Revisit Every OncLive On Air Episode From November 2025

In case you missed any, below is a recap of the episodes of OncLive On Air® that debuted in November 2025. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

Oncology Experts Dive Into Top Data From ESMO 2025

In this episode, experts across oncology specialties highlighted some of the most exciting findings in breast, genitourinary, and gynecologic cancer research that were presented at the 2025 ESMO Congress.

“For the first time, we saw that fan-trastuzumab deruxtecan-nxki [Enhertu] has a role in the early-stage, curative [HER2-positive breast cancer] setting,” said Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute in Boston, Massachusetts.

“The future of the enfortumab vedotin-ejfv [Padcev]/pembrolizumab [Keytruda] combination will shift our considerations, [since we have] never used it…earlier in [the muscle-invasive bladder cancer (MIBC) disease course],” added Andrea Necchi, MD, of Vita-Salute San Raffaele University in Milan, Italy.

“[The phase 2 OPTIC RCC trial (NCT05361720)] answered a really important and provocative question, which is: can we start using biomarkers to choose the right patient for the right first-line treatment [for those with metastatic clear cell renal cell carcinoma]?” noted Andrew W. Hahn, MD, of The University of Texas MD Anderson Cancer Center in Houston.

“To see another antibody-drug conjugate [ADC] being developed [for ovarian cancer] is interesting, [provided that it shows a] tolerable safety profile and a good efficacy comparable to the other ADCs that we're seeing presented,” stated Dana M. Chase, MD, of UCLA.

Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS

In part 1 of the 3-part limited series titled Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, host Martha K. Terris, MD, FACS, of the Medical College of Georgia at Augusta University, explained the incidence of bladder cancer in women and reasons leading to diagnostic disparities that disproportionately affect women and are associated with poor treatment outcomes.

“The most common [reason why doctors miss bladder cancer in women is when] women come [into the doctor’s office] with blood in their urine,” Terris said. “I see so many women come into my clinic with advanced bladder cancer, and they’ve had a year or two of multiple emergency department visits or multiple primary care visits complaining of blood in their urine and are given antibiotics, and nobody thinks to look for anything else.”

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

In this episode, Sikander Ailawadhi, MD, of Mayo Clinic in Jacksonville, Florida; and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO, of Cleveland Clinic in Ohio, highlighted the findings and clinical implications of the phase 3 IRAKLIA (NCT05405166) and phase 2 IZALCO (NCT05704049) studies of isatuximab-irfc (Sarclisa) administered via an on-body delivery system in patients with relapsed/refractory multiple myeloma.

“[The IRAKLIA] study had a unique aspect, which is that after 6 cycles of treatment…the patients who were getting the subcutaneous on-body injector could opt to get it at their home,” Ailawadhi noted. “I had a couple patients who opted to take it at home, and they were excited about the fact that now they’re getting a monoclonal antibody immunotherapy drug in the convenience of their home. That was remarkable.”

“This on-body injector [makes treatment] easy to administer,” Faiman added. “In clinical studies, most of the drug was administered. That allows the patient to get in the chair, and [the nurse puts] the on-body device on, and that frees them up to do other activities, such as tend to another patient’s needs or hang an IV in another room.”

ARROS-1 Data Show Zidesamtinib’s Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

In this episode, Stephen Liu, MD, of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, explained the current standards of care for the management of ROS1-positive non–small cell lung cancer (NSCLC), the unique mechanism of action of zidesamtinib (NVL-520), and the clinical implications of data from the phase 1/2 ARROS-1 trial (NCT05118789).

“[We saw] promising efficacy, [including] greater efficacy in the TKI-naive setting [and] impressive efficacy in the previously treated setting,” Liu highlighted. “This is a drug that blows us away as initial therapy.”

Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO

In this episode, Kevin Kalinsky, MD, MS, FASCO, of the Winship Cancer Institute in Atlanta, Georgia, spotlighted combination therapies that may positively affect the hormone receptor–positive breast cancer treatment paradigm for patients who have received prior endocrine therapy, factors influencing treatment selection following prior CDK4/6 inhibition, best practices for genomic testing, and notable breast cancer data from the 2025 ESMO Congress.

“Additional endocrine-based treatments, along with targeted therapies, could improve how patients do post–CDK4/6 inhibition with endocrine therapy, which we commonly give as frontline therapy,” Kalinsky reported.

Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

In this episode, Hira Mian, MD, MSc, FRCPC, of McMaster University in Toronto, Canada, talked through the importance of assessing dynamic frailty in the treatment of transplant-ineligible patients with newly diagnosed multiple myeloma, as seen in the results of a dynamic frailty analysis of the phase 3 MAIA (NCT02252172) and CEPHEUS (NCT03652064) trials presented at the 2025 International Myeloma Society Annual Meeting.

“This emphasizes that you can’t use a one-time frailty measurement; you need to be more dynamic,” Mian emphasized. “When we started looking at specific outcomes in terms of efficacy, minimal residual disease negativity rates, and progression-free survival, it was great to see that both for CEPHEUS and MAIA, [the addition of] daratumumab [Darzalex] ended up helping all the subgroups dynamically across the different time points.”

Urothelial ESMO 2025 Updates

In this episode of Two Onc Docs, hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis; and Karine Tawagi, MD, of the University of Illinois in Chicago, reviewed key bladder cancer data from the 2025 ESMO Congress.

“There were many updates in bladder cancer that have the potential to change guidelines,” Tawagi emphasized.

“I love that we’re using circulating tumor DNA [in a] smarter [way] now so that may come to fruition for changing therapies for MIBC,” Armstrong added.

Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS

In part 2 of 3 of Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, Dr Terris explained factors that may contribute to disparities in treatment outcomes for women with bladder cancer.

“Women tend to have worse tolerability of immunotherapy and higher rates of discontinuation and poor efficacy regardless of the tolerability,” Terris said.

How a Career Dedicated to Patient Connections and Research Advances Has Improved Lung Cancer Care: With D. Ross Camidge, MD, PhD; and Mark Socinski, MD

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, sat down with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida, to talk through Dr Socinski’s career highlights, including his pioneering of dose-escalation trials using conformal radiotherapy and his involvement in building the AdventHealth Cancer Institute into a major cancer program.

“I stumbled into having a career in lung cancer,” Socinski explained. “I view myself somewhere between a clinician and a clinical investigator.”

“The idea that progress could still be made even with the relatively blunt instruments we had at the time [is interesting],” Camidge added. “You started to make your name in next-generation chemotherapy.”

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

In this inaugural episode of From Discovery to Delivery: Charting Progress in Gynecologic Oncology, host Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Taymaa May, MD, MSc, of the Brigham and Women’s Hospital in Boston, discussed notable evolutions in the field of minimally invasive surgery for patients with gynecologic cancers.

“It’s important for patients with newly diagnosed, suspected, or confirmed gynecologic cancers—whether endometrial, ovarian, cervical, or vulvar cancer or otherwise—to be assessed by a gynecologic oncology surgeon,” May emphasized.

“Since some of the most catastrophic complications I’ve seen from surgery have been dehiscence of bowel loops, [fluorescence angiography] sounds like a significant step forward,” Matulonis described.

PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

In this episode, host Benjamin P. Levy, MD, of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital in Washington, DC, sat down with Scott T. Tagawa, MD, MS, FACP, FASCO, of Weill Cornell Medicine in New York, New York, to chat about all things related to the management of kidney and prostate cancers.

“[There have been] a lot of notable highlights regarding the evolution of the PSMA-positive prostate cancer treatment paradigm,” Levy summarized.

“Therapy has been codeveloped with imaging,” Tagawa added. “We can do a scan and look at each individual lesion and have an in vivo assessment of a target.”

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

In this episode, host Benjamin P. Levy, MD, sat down with Jonathan W. Lee, MD, MSc, of Weill Cornell Medicine, to talk through the evolution of therapies for patients with HER2-positive and EGFR-mutated NSCLC.

“Leading the precision medicine story is the EGFR-mutated setting,” Levy stated. “We’ve witnessed transformative studies in the past 1 to 2 years.”

“The [phase 3] FLAURA2 trial [NCT04035486] regimen, which is the combination of osimertinib [Tagrisso] and chemotherapy in the frontline setting, is a popular regimen [among] my co-fellows across the United States,” Lee added. “It’s an attractive option given how dynamic and flexible it can be.”

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

In this episode, host Benjamin P. Levy, MD, invited Kamel Abou Hussein, MD, of Cooper University Health Care in Camden, New Jersey; and Victoria Rizk, MD, of Tampa General Hospital Cancer Institute in Florida, to chat about exciting breast cancer treatment developments.

“ADCs [represent] one of these areas where we’re learning in lung cancer a lot about what’s going on in breast cancer,” Levy contextualized.

“Breast cancer is a pioneer when it comes to ADCs and management in general for [patients with] complex metastatic [disease],” Rizk added.

“There was a lot of hope that ADCs were going to make their way to the algorithm of treatment of different subtypes, and they have set the standard for the treatment of HER2-positive, HER2-low, and triple-negative breast cancer,” Abou Hussein explained.

Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS

In the final part of this 3-part series, host Martha K. Terris, MD, FACS, explained the unique diagnostic challenges faced by women with bladder cancer.

“One of our biggest risk groups is people who work in textile mills,” Terris noted. “Another one is hairdressers. The dyes used to color hair are also a potent risk for bladder cancer.”

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD

In this OncClub episode, Justin Taylor, MD, of University of Miami Miller School of Medicine, spoke about the evolving use of artificial intelligence (AI) among patients with cancer and the implications for clinicians who treat these patients.

“With AI tools being readily accessible, patients are turning to it for information,” Taylor said. “We should be interested in what kind of information our patients are getting online. The reason that we wanted to do this study was to test the accuracy of what these AI tools are telling patients if they’re asking for information from them.”

FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD

In this episode, Harry P. Erba, MD, PhD, of Duke Cancer Institute in Durham, North Carolina, highlighted the significance of the FDA approval of ziftomenib (Komzifti) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.

“It’s important to recognize that given that responses were only seen in approximately one-quarter of the patients [who received ziftomenib in the phase 1/2 KOMET-001 trial (NCT04067336), this outcome] compares favorably with intensive and less-intensive chemotherapies,” Erba highlighted.

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

In this episode, Marc S. Raab, MD, of Heidelberg University in Germany, noted findings from minimal residual disease analyses from the phase 2 MajesTEC-5 study (NCT05695508) of teclistamab-cqyv (Tecvayli)–based induction regimens in patients with newly diagnosed multiple myeloma.

“We found that the response rates not only deepened over time, but [we] almost reached a 100% complete response [rate] across all cohorts,” Raab explained.

Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD

In this episode, Daniel Spratt, MD, of the Case Comprehensive Cancer Center in Cleveland, Ohio, discussed advances in molecular imaging, systemic therapy, and androgen deprivation therapy may reconfigure the prostate cancer treatment paradigm.

“Predictive biomarkers that have undergone recent testing and validation will continue to identify which patients molecularly or biologically do not benefit or benefit minimally from hormone therapy,” Spratt explained.

How An Interest in Translational Research and Drug Development Helps Evolve Regulatory Practices: With D. Ross Camidge, MD, PhD; and Gideon Blumenthal, MD

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, sat down with Gideon Blumenthal, MD, of Merck in Silver Spring, Maryland, to chat about Dr Blumenthal's career, notable highlights of which include roles at the FDA and in industry.

“My guest today is someone who’s been on both sides of the regulatory divide in oncology,” Camidge introduced.

“We’re at this interesting inflection point in oncology where we’ve tasted the promise of some modalities, including immune checkpoint inhibitors…and targeted therapies,” Blumenthal summarized. “T-cell engagers are now starting to come into solid tumors. We have ADCs…. There’s so much possibility now…. That motivates me for what the future holds in oncology.”

Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS

In this episode, Cassie Kline, MD, MAS, of Children's Hospital of Philadelphia in Pennsylvania, discussed longer-term efficacy findings from the phase 2 FIREFLY-1 study (NCT04775485) investigating tovorafenib (Ojemda) in patients with relapsed/refractory pediatric low-grade glioma that were presented at the 2025 Society of Neuro-Oncology Annual Meeting.

“The time to next treatment being over 40 months for our patient population, ideally, is giving our patients and families this nice long period of not necessarily needing additional therapies,” Kline emphasized.

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

In this episode, Joshua Richter, MD, of Mount Sinai in New York, noted the rationale for, key findings from, and potential future clinical implications of the phase 1 CAMMA 1 study (NCT04910568) of combinations containing the bispecific antibody cevostamab (RG6160; BFCR4350A) in patients with relapsed/refractory multiple myeloma.

“As we start to look into combination strategies with bispecific antibodies, you're going to see a lot of studies like CAMMA 1 that start incorporating immunomodulatory drugs like lenalidomide [Revlimid] or pomalidomide [Pomalyst],” according to Richter.

Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD

In this episode, Jacob Sands, MD, of Dana-Farber Cancer Institute; and Shailee Shah, MD, of Northwestern University Feinberg School of Medicine in Chicago, explained notable considerations for the diagnosis and treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS), particularly when it is associated with small cell lung cancer (SCLC).

“The symptoms of LEMS are quite common in general,” Sands described. “A patient with SCLC, especially on treatment, [may feel] some weakness, which is one of the more classic symptoms of LEMS. When any [symptoms are] going on neurologically without a good description, I would consider paraneoplastic syndromes associated with SCLC.”

“It can be challenging sometimes, even for a neurologist, to recognize and identify some of these subtle symptoms that can arise and try to establish a diagnosis as quickly as possible,” Shah added.